Free Trial
NASDAQ:SLRX

Salarius Pharmaceuticals Q3 2023 Earnings Report

Salarius Pharmaceuticals logo
$4.64 -0.01 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.73 +0.09 (+1.94%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Salarius Pharmaceuticals EPS Results

Actual EPS
-$78.00
Consensus EPS
-$128.40
Beat/Miss
Beat by +$50.40
One Year Ago EPS
N/A

Salarius Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Salarius Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Salarius Pharmaceuticals' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Thursday, November 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Salarius Pharmaceuticals Earnings Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More Salarius Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Salarius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Salarius Pharmaceuticals and other key companies, straight to your email.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals (NASDAQ:SLRX) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults. Seclidemstat is currently being evaluated in Phase 2 clinical studies, where the company is investigating its efficacy and safety profile in patients with relapsed or refractory disease.

In addition to its lead program, Salarius maintains a robust preclinical pipeline of small‐molecule candidates targeting fusion‐driven cancers and other oncology indications. These programs leverage proprietary chemistry platforms to identify novel inhibitors of NEDD8‐activating enzymes and other epigenetic regulators. By addressing oncogenic fusion proteins and key regulatory enzymes that drive tumor growth, Salarius aims to expand its portfolio of precision therapies for patients with unmet medical needs.

Founded in 2014 and headquartered in Houston, Texas, Salarius Pharmaceuticals has assembled a management team with extensive experience in oncology drug development, regulatory strategy, and commercialization. The company’s clinical trials are conducted primarily in the United States, with plans to extend development activities into Europe and other regions as part of its global strategy. Salarius also collaborates with academic institutions, patient advocacy groups and research consortia to advance its programs and accelerate the delivery of new cancer therapies to the clinic.

View Salarius Pharmaceuticals Profile

More Earnings Resources from MarketBeat